With enlicitide, large LDL cholesterol reductions possible without a needle
— With enlicitide, large LDL cholesterol reductions possible without a needle
by Nicole Lou, Senior Staff Writer, MedPage Today
July 16, 2026
• 2 min read
The FDA approved enlicitide (Lipfendra) as the first oral PCSK9 inhibitor for lowering cholesterol.
Merck and the FDA announced the approval of enlicitide 20 mg as an add-on to diet and exercise to lower LDL in adults with…
A new Merck pill called enlicitide slashes levels of harmful LDL cholesterol by up to 60%, similar to injectable PCSK9 drugs…
El organismo regulador de medicinas de los EE. UU. autorizó el uso recetado de “enlicitide”. Este medicamento reduce en hasta un…
The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in…
Merck’s pill, called Lipfendra, is a PCSK9 inhibitor, which works in a different way than a statin to lower cholesterol.
Merck's Lipfendra wins FDA approval as the first oral PCSK9 inhibitor for adults with high LDL cholesterol after positive Phase 3…
